Investigational drug · Phase 2
GT201
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors, Advanced Solid Tumors Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
10
Any phase or sponsor naming "GT201"
First trial start
2025
Nov 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GT201", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
- Advanced Solid Tumors Cancer
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "GT201" as an intervention, largest first.
Grit BiotechnologyIndustry
NCT06144671 · 78 participants (planned) · Start Nov 1, 2025 · Primary completion Dec 30, 2027
Drug: GT201; IL-2 and 1 more · For: Advanced Solid Tumors
Sites: Guangzhou, China; Nanning, China; Changsha, China · 6 sites in all
- Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion.Not yet recruiting
Gritbio Medicine, Inc.Industry
NCT07766317 · 63 participants (planned) · Start Nov 2026 · Primary completion Jun 2030
Drug: GT201; IL-2 and PD-1 · For: Advanced Solid Tumors Cancer
- Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck TumorsRecruiting
Grit BiotechnologyIndustry
NCT06190275 · 32 participants (planned) · Start May 12, 2024 · Primary completion Apr 30, 2027
Drug: GT201 in combination with PD-1 inhibitors · For: HNSCC
Sites: Shanghai, China
- Exploratory Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Gynecologic TumorsStatus unknown
RenJi HospitalAcademic, hospital or other
NCT05724732 · 24 participants (planned) · Start Feb 1, 2023 · Primary completion May 1, 2025
Drug: GT201 · For: Solid Tumor
Sites: Shanghai, China
Grit BiotechnologyIndustry
NCT05729399 · 6 participants · Start Sep 14, 2022 · Primary completion Dec 30, 2025
Drug: GT201 · For: Solid Tumor
Sites: Zhengzhou, China; Suzhou, China; Xuzhou, China
- Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)Terminated
Grit BiotechnologyIndustry
NCT06191900 · 4 participants · Start Jun 5, 2023 · Primary completion Dec 30, 2025
Drug: Autologous tumor infiltrating lymphocyte injection(GT201) · For: Adult; Gynecological Tumors
Sites: Shanghai, China
Grit BiotechnologyIndustry
NCT06519669 · 2 participants · Start Jul 18, 2024 · Primary completion Dec 30, 2025
Drug: GT201 injection · For: Adult; Lung Cancer
Sites: Beijing, China; Shanghai, China
Grit BiotechnologyIndustry
NCT05430360 · 2 participants · Start Jan 4, 2022 · Primary completion Dec 30, 2025
Drug: GT201 · For: Solid Tumor
Sites: Hangzhou, China
Grit BiotechnologyIndustry
NCT06235242 · 2 participants · Start Feb 2, 2024 · Primary completion Dec 30, 2025
Drug: GT201 injection in combination with teraplizumab injection · For: Adult; Non-small Cell Lung Cancer
Sites: Beijing, China; Shanghai, China · 3 sites in all
Grit BiotechnologyIndustry
NCT06834542 · 1 participants · Start Nov 1, 2022 · Primary completion Dec 30, 2025
Drug: Autologous tumor infiltrating lymphocyte injection(GT201) · For: Adult Gynecological Tumors
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Novel tumor-infiltrating lymphocytes therapy in solid tumors: latest updates from 2025 ASCO annual meeting.
Ma Y, Su X, Feng H · Exp Hematol Oncol 2025
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.